

19 February 2020

Helsinki, Finland

Press Release – Patent granted in Brazil to LS CancerDiag for its DiagMMR® innovation

LS CancerDiag gets the patent granted in Brazil for its innovative DiagMMR® test.

The largest country in Latin America completes the already impressive patent portfolio of LS CancerDiag. Brazil brings the total count to 29 countries across the world.

As a result, the list of countries now covers all major markets in Europe, the Americas and Asia. The largest countries of the European Union are included, as well as the United States and Canada. They had granted the patents in 2018, following Russia, Japan, and China. However, Australia was leading the way all the way back in 2015. It was the first country to grant the patent to LS CancerDiag.



Patent coverage for DiagMMR®

LS CancerDiag has successfully applied for patents and secured a very strong IP position globally. These efforts culminate with the patent granted in Brazil, underlining the strong IP strategy which the company has followed since its founding.

The latest developments emphasize the innovation power of LS CancerDiag with its predictive quantitative test. This supports the company's ambition to improve Lynch syndrome detection at a global scale. The patent portfolio gives the company a unique position for expanding into new markets with DiagMMR®. □

About LS CancerDiag Ltd

LS CancerDiag is committed to reducing cancer mortality rates with a simple and accurate diagnostic method that detects an inherited cancer-causing condition prior to cancer and enables preventive and personalized care. Lynch syndrome (previously known as Hereditary Non-Polyposis Colorectal Cancer; HNPCC) is the main cause of hereditary colorectal cancers, but it is also linked to endometrial cancer and various other types of tumors. With its high prevalence in the world's population and the currently very low diagnosis rates, there are millions of people with Lynch syndrome without being aware of it. The groundbreaking DiagMMR® assay is an easy functional test that can be used for diagnosis of MMR deficiency, the key characteristic of Lynch syndrome. The company mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome by delivering predictive and accurate results globally with a fast, unique and cost-efficient method.

Contact information

Philippe Arnez, Chief Business Officer
philippe.arnez@lscancerdiag.com

LS CancerDiag Ltd 
@LSCancerDiag 

<http://www.lscancerdiag.com>